Management of Patients with Liver Derangement During the COVID-19 Pandemic: an Asia-Pacific Position Statement

Overview

Journal Lancet Gastroenterol Hepatol

Specialty Gastroenterology

Date 2020 Jun 26

PMID 32585136

Citations 54

Authors

Grace Lai-Hung Wong

Vincent Wai-Sun Wong

Alex Thompson

Jidong Jia

Jinlin Hou

Cosmas Rinaldi Adithya Lesmana

Adityo Susilo

Yasuhito Tanaka

Wah-Kheong Chan

Ed Gane

Arlinking K Ong-Go

Seng-Gee Lim

Sang Hoon Ahn

Ming-Lung Yu

Teerha Piratvisuth

Henry Lik-Yuen Chan

Affiliations

Soon will be listed here.

Abstract

The COVID-19 pandemic has spread rapidly worldwide. It is common to encounter patients with COVID-19 with abnormal liver function, either in the form of hepatitis, cholestasis, or both. The clinical implications of liver derangement might be variable in different clinical scenarios. With growing evidence of its clinical significance, it would be clinically helpful to provide practice recommendations for various common clinical scenarios of liver derangement during the COVID-19 pandemic. The Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic was formed to systematically review the literature with special focus on the clinical management of patients who have been or who are at risk of developing liver derangement during this pandemic. Clinical scenarios covering the use of pharmacological treatment for COVID-19 in the case of liver derangement, and assessment and management of patients with chronic hepatitis B or hepatitis C, non-alcoholic fatty liver disease, liver cirrhosis, and liver transplantation during the pandemic are discussed.

Citing Articles

Factors associated with the perception of resentment towards the Chinese in Latin America during the first wave of the COVID-19 pandemic.

Mejia C, Ascarza G, Alvarez-Risco A, Misayauri J, Arias-Chavez D, Vilela-Estrada M BMC Public Health. 2024; 24(1):3226.

PMID: 39567946 PMC: 11577586. DOI: 10.1186/s12889-024-20568-9.

Pharmacological considerations in pharmacotherapy of rheumatology patients with liver disease: a brief narrative review.

Shenavandeh S, Taghavi S, Nekooeian A, Moini M Reumatologia. 2024; 62(4):282-293.

PMID: 39381733 PMC: 11457314. DOI: 10.5114/reum/191791.

Insight into COVID-19 associated liver injury: Mechanisms, evaluation, and clinical implications.

Nasir N, Khanum I, Habib K, Wagley A, Arshad A, Majeed A Hepatol Forum. 2024; 5(3):139-149.

PMID: 39006140 PMC: 11237249. DOI: 10.14744/hf.2023.2023.0025.

Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry.

Schimmel J, Epperson L, Aldy K, Wax P, Brent J, Buchanan J Drugs. 2024; 84(2):209-217.

PMID: 38198063 DOI: 10.1007/s40265-023-01981-7.

Reply.

Wong G, Hui V, Yip T Gastroenterology. 2023; 165(1):306.

PMID: 37044273 PMC: 10085869. DOI: 10.1053/j.gastro.2023.03.232.

References

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

Stein R . COVID-19 and rationally layered social distancing. Int J Clin Pract. 2020; 74(7):e13501. PMC: 7228406. DOI: 10.1111/ijcp.13501. View

Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K . Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59(3):252-6. PMC: 1746980. DOI: 10.1136/thorax.2003.012658. View

DAntiga L . Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. Liver Transpl. 2020; 26(6):832-834. DOI: 10.1002/lt.25756. View

Wang J, Chang K, Kee K, Chen P, Yen Y, Tseng P . Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol. 2013; 108(3):416-24. DOI: 10.1038/ajg.2012.445. View

Wong G, Kwok R, Hui A, Tse Y, Ho K, Lo A . A new screening strategy for varices by liver and spleen stiffness measurement (LSSM) in cirrhotic patients: A randomized trial. Liver Int. 2017; 38(4):636-644. DOI: 10.1111/liv.13560. View

Huang C, Yu M . Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy. Clin Mol Hepatol. 2020; 26(3):251-260. PMC: 7364348. DOI: 10.3350/cmh.2020.0018. View

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

10.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

11.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

12.

. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017; 2(3):161-176. DOI: 10.1016/S2468-1253(16)30181-9. View

13.

Poordad F . Presentation and complications associated with cirrhosis of the liver. Curr Med Res Opin. 2015; 31(5):925-37. DOI: 10.1185/03007995.2015.1021905. View

14.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

15.

Emanuel E, Persad G, Upshur R, Thome B, Parker M, Glickman A . Fair Allocation of Scarce Medical Resources in the Time of Covid-19. N Engl J Med. 2020; 382(21):2049-2055. DOI: 10.1056/NEJMsb2005114. View

16.

Shang L, Zhao J, Hu Y, Du R, Cao B . On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020; 395(10225):683-684. PMC: 7159292. DOI: 10.1016/S0140-6736(20)30361-5. View

17.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

18.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

19.

Xu L, Liu J, Lu M, Yang D, Zheng X . Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020; 40(5):998-1004. PMC: 7228361. DOI: 10.1111/liv.14435. View

20.

Zhou J, Tan J . Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China. Metabolism. 2020; 107:154216. PMC: 7102634. DOI: 10.1016/j.metabol.2020.154216. View